Dulaglutide (Trulicity) studies: 418 papers with results
Page 5 of 9
- Once Weekly Dulaglutide Therapy in Type 2 Diabetic Subjects, Real-world Evidence from a Tertiary Care Diabetes Center in India.
Wasir JS · Indian journal of endocrinology and metabolism · 2018
Observational study · 7 results
- Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment.
Chen S · Diabetes, metabolic syndrome and obesity : targets and therapy · 2024
Observational study · 10 results
- Glycemic Improvement with Low-Dose Dulaglutide Is Associated with Leptin and Obestatin Modulation in Type 2 Diabetes Mellitus.
Jung I · Diabetes & metabolism journal · 2026
Observational study · 12 results
- Comparing Quality of Life in Type 2 Diabetic Patients Using Dulaglutide and Liraglutide
Ghosh A · Journal of the Endocrine Society · 2021
Observational study · 2 results
- Exploring a Suitable Marker of Glycemic Response to Dulaglutide in Patients with Type 2 Diabetes: A Retrospective Study.
Yoshiji S · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2022
Observational study · 3 results
- Dulaglutide 1.5 mg Significantly Improves Glycemic Control and Lowers LDL-Cholesterol and Body Weight in Romanian Patients with Type 2 Diabetes.
Bobu AM · Journal of clinical medicine · 2025
Observational study · 8 results
- Vascular and Myocardial Function in Patients with Type 2 Diabetes and Ischemic Stroke Treated with Dulaglutide or Empagliflozin.
Pavlidis G · Medicina (Kaunas, Lithuania) · 2026
Observational study · 10 results
- Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis.
Guirguis A · European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2024
Observational study · 16 results
- Effects of dapagliflozin and dulaglutide on blood pressure and coronary flow in liver steatosis patients with type 2 diabetes.
Ikonomidis I · Journal of hypertension · 2026
Observational study · 14 results
- Metabolic remodeling of glycerophospholipids acts as a signature of dulaglutide and liraglutide treatment in recent-onset type 2 diabetes mellitus.
Du J · Frontiers in endocrinology · 2022
Observational study · 6 results
- Efficacy of dulaglutide after switching from incretin-related drugs in patients with type 2 diabetes and inadequate glycemic control.
Ito H · Diabetology international · 2022
Observational study · 5 results
- Efficacy and safety profile of Glucagon-Like Peptide-1 Receptor Agonist in obese Type-2 diabetes patients from a private institution in Karachi.
Qasim SF · Pakistan journal of medical sciences · 2023
Observational study · 16 results
- Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus.
Seko Y · Hepatology research : the official journal of the Japan Society of Hepatology · 2017
Observational study · 5 results
- Durability of Glucose-Lowering Effect of the First Administration of Dulaglutide: A Retrospective, Single-Center, Single-Arm Study.
Matsushita M · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2018
Observational study · 4 results
- Endothelial Function in Patients with Multiple Sclerosis: The Role of GLP-1 Agonists, Lipoprotein Subfractions, and Redox Balance.
Hardonova M · International journal of molecular sciences · 2023
Observational study · 3 results
- Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study.
Kuwata H · Journal of diabetes investigation · 2021
Observational study · 12 results
- Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration's FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset.
Chiappini S · Pharmaceuticals (Basel, Switzerland) · 2023
Observational study · 7 results
- Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting.
Uzoigwe C · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2021
Observational study · 15 results
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®).
McIntyre RS · Journal of affective disorders · 2025
Observational study · 13 results
- Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials.
Tuttle KR · Diabetes, obesity & metabolism · 2017
Observational study · 8 results
- Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials.
Pozzilli P · Diabetes, obesity & metabolism · 2018
Observational study · 6 results
- Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events.
He L · Frontiers in pharmacology · 2024
Observational study · 17 results
- Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice.
Krüger N · Nature medicine · 2026
Observational study · 5 results
- Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment.
Umpierrez GE · Diabetes, obesity & metabolism · 2016
Observational study · 8 results
- Correlation between intestinal flora and GLP-1 receptor agonist dulaglutide in type 2 diabetes mellitus treatment-A preliminary longitudinal study.
Liang L · iScience · 2024
Observational study · 4 results
- Assessing adverse drug reaction reports for antidiabetic medications approved by the food and drug administration between 2012 and 2017: a pharmacovigilance study.
Stottlemyer BA · Therapeutic advances in drug safety · 2023
Observational study · 2 results
- Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study.
Ghosal S · Clinical diabetes and endocrinology · 2018
Observational study · 10 results
- Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database.
Shirani A · Therapeutic advances in neurological disorders · 2024
Observational study · 3 results
- Otolaryngologic Side Effects of GLP-1 Receptor Agonists.
Khan FI · The Laryngoscope · 2025
Observational study · 20 results
- The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months.
Guerci B · Diabetes, obesity & metabolism · 2022
Observational study · 8 results
- Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohort study.
Chen SY · European heart journal. Cardiovascular pharmacotherapy · 2025
Observational study · 28 results
- Therapeutic inertia related to the injectable glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes in UK primary care.
von Arx LB · Diabetes, obesity & metabolism · 2023
Observational study · 6 results
- Real-world persistence and dose titration of GLP-1 receptor agonists in type 2 diabetes: A UK population-based cohort study by obesity and cardiovascular disease status.
Ulrich FS · Diabetes, obesity & metabolism · 2026
Observational study · 18 results
- Semaglutide and diabetic retinopathy: an OHDSI network study.
Cai CX · BMJ open diabetes research & care · 2025
Observational study · 10 results
- The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months.
Boye KS · Diabetes, obesity & metabolism · 2023
Observational study · 7 results
- Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study.
Anthony MS · Diabetes care · 2024
Observational study · 6 results
- Addition of Dulaglutide or Empagliflozin to Standard-of-Care Treatment: Effect on Liver Steatosis in Patients With Type 2 Diabetes Mellitus.
Koullias E · Cureus · 2024
Observational study · 3 results
- Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study.
Sanada J · Frontiers in endocrinology · 2021
Observational study · 3 results
- Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study.
Kimura T · Journal of diabetes research · 2024
Observational study · 8 results
- Risk of Dementia after initiation of GLP-1 RA versus long-acting insulin in patients with type 2 Diabetes mellitus.
Lin CH · The journal of prevention of Alzheimer's disease · 2026
Observational study · 10 results
- Cohort Study: Risk of Gallstones and Biliary Complications With Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes.
Eldesouki MH · United European gastroenterology journal · 2026
Observational study · 24 results
- Improvement in Helicobacter pylori Eradication Among Adults Receiving Semaglutide: A Population-Based Propensity-Score-Adjusted Analysis.
Ness A · Helicobacter · 2025
Observational study · 7 results
- Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes Mellitus in France and Italy: A Retrospective Cohort Study.
Khare S · Advances in therapy · 2025
Observational study · 6 results
- Audiovestibular adverse event reporting profiles of GLP-1 receptor agonists: A case-case pharmacovigilance study using FDA AEMS data.
Wang X · European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
Observational study · 7 results
- Pancreatic and biliary safety signals of GLP-1 receptor agonists and tirzepatide: a disproportionality analysis of FAERS reports.
Wu Y · Frontiers in endocrinology · 2026
Observational study · 6 results
- Assessing the Association Between GLP-1 Receptor Agonists and Diabetic Foot Complications Using Real-World Pharmacovigilance Database and Mendelian Randomization.
Zhang T · The international journal of lower extremity wounds · 2026
Observational study · 9 results
- Glucagon-like peptide-1 receptor agonist-associated injection site and dermatologic reactions.
Elgindi D · Clinics in dermatology · 2026
Observational study · 8 results
- Semaglutide and Neovascular Age-Related Macular Degeneration among Adults with Type 2 Diabetes: An Observational Health Data Sciences and Informatics Network Study.
Cai CX · Ophthalmology · 2026
Observational study · 8 results
- Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis.
Lin S · Andrology · 2026
Observational study · 4 results
- Association between incretin-related drugs and fractures in patients treated with pioglitazone: A pharmacovigilance study using the FDA Adverse Event Reporting System.
Ohyama K · International journal of clinical pharmacology and therapeutics · 2026
Observational study · 3 results